Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ENZN's Cash to Debt is ranked higher than
90% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. ENZN: No Debt )
ENZN' s 10-Year Cash to Debt Range
Min: 0.22   Max: No Debt
Current: No Debt

Equity to Asset 0.94
ENZN's Equity to Asset is ranked higher than
96% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ENZN: 0.94 )
ENZN' s 10-Year Equity to Asset Range
Min: -0.25   Max: 0.94
Current: 0.94

-0.25
0.94
Interest Coverage 8.55
ENZN's Interest Coverage is ranked higher than
53% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZN: 8.55 )
ENZN' s 10-Year Interest Coverage Range
Min: 0.24   Max: 9999.99
Current: 8.55

0.24
9999.99
F-Score: 7
Z-Score: 22.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 77.30
ENZN's Operating margin (%) is ranked higher than
99% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. ENZN: 77.30 )
ENZN' s 10-Year Operating margin (%) Range
Min: -111.06   Max: 52.65
Current: 77.3

-111.06
52.65
Net-margin (%) 80.15
ENZN's Net-margin (%) is ranked higher than
99% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -69.57 vs. ENZN: 80.15 )
ENZN' s 10-Year Net-margin (%) Range
Min: -53.9   Max: 179.23
Current: 80.15

-53.9
179.23
ROE (%) 179.91
ENZN's ROE (%) is ranked higher than
100% of the 877 Companies
in the Global Biotechnology industry.

( Industry Median: -28.59 vs. ENZN: 179.91 )
ENZN' s 10-Year ROE (%) Range
Min: -49.06   Max: 91.08
Current: 179.91

-49.06
91.08
ROA (%) 157.87
ENZN's ROA (%) is ranked higher than
100% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. ENZN: 157.87 )
ENZN' s 10-Year ROA (%) Range
Min: -25.24   Max: 42.7
Current: 157.87

-25.24
42.7
ROC (Joel Greenblatt) (%) 7876.27
ENZN's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. ENZN: 7876.27 )
ENZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -501.03   Max: 3191.39
Current: 7876.27

-501.03
3191.39
Revenue Growth (%) -25.90
ENZN's Revenue Growth (%) is ranked higher than
65% of the 646 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ENZN: -25.90 )
ENZN' s 10-Year Revenue Growth (%) Range
Min: -40.6   Max: 95.5
Current: -25.9

-40.6
95.5
EBITDA Growth (%) 38.70
ENZN's EBITDA Growth (%) is ranked higher than
97% of the 621 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. ENZN: 38.70 )
ENZN' s 10-Year EBITDA Growth (%) Range
Min: -55.1   Max: 66.5
Current: 38.7

-55.1
66.5
» ENZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ENZN Guru Trades in Q3 2013

Charles Brandes 1,027,743 sh (+0.1%)
Seth Klarman 7,691,453 sh (unchged)
Michael Price 748,200 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
First Pacific Advisors 377,035 sh (-0.73%)
Jim Simons 819,984 sh (-9.92%)
» More
Q4 2013

ENZN Guru Trades in Q4 2013

Paul Tudor Jones 36,398 sh (New)
Michael Price 748,200 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
Charles Brandes 1,023,893 sh (-0.37%)
Jim Simons 765,284 sh (-6.67%)
First Pacific Advisors 347,035 sh (-7.96%)
Seth Klarman 4,337,858 sh (-43.6%)
» More
Q1 2014

ENZN Guru Trades in Q1 2014

Jim Simons 971,984 sh (+27.01%)
Charles Brandes 1,048,423 sh (+2.4%)
Paul Tudor Jones 36,398 sh (unchged)
Michael Price 748,200 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
First Pacific Advisors 347,035 sh (unchged)
Seth Klarman Sold Out
» More
Q2 2014

ENZN Guru Trades in Q2 2014

George Soros 50,123 sh (New)
Jim Simons 1,118,184 sh (+15.04%)
First Pacific Advisors 347,035 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
Paul Tudor Jones 36,398 sh (unchged)
Michael Price 748,200 sh (unchged)
Charles Brandes 1,043,363 sh (-0.48%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 New Buy$0.81 - $1.18 $ 1.0915%50123
Seth Klarman 2014-03-31 Sold Out 0.14%$0.861 - $1.26 $ 1.095%0
Seth Klarman 2013-12-31 Reduce -43.6%0.16%$1.15 - $1.74 $ 1.09-29%4337858
Charles Brandes 2013-06-30 Add 184.52%0.02%$1.6 - $3.95 $ 1.09-63%1026723
Charles Brandes 2013-03-31 Add 432.17%0.01%$3.79 - $4.99 $ 1.09-76%360865
Jean-Marie Eveillard 2012-12-31 Sold Out 0.01%$4.35 - $7 $ 1.09-82%0
Charles Brandes 2012-12-31 Add 35.19%$4.35 - $7 $ 1.09-82%67810
Jean-Marie Eveillard 2012-09-30 Reduce -56.42%0.02%$6.42 - $7.17 $ 1.09-84%490142
Charles Brandes 2012-06-30 Add 58.41%$5.87 - $7.06 $ 1.09-83%51070
Charles Brandes 2012-03-31 New Buy$6.54 - $7.82 $ 1.09-84%32240
Richard Perry 2011-09-30 Sold Out 0.5937%$7.24 - $10.37 $ 1.09-88%0
Carl Icahn 2011-09-30 Add 25%0.07%$7.24 - $10.37 $ 1.09-88%5904863
Richard Perry 2011-06-30 Reduce -30.35%0.31%$9.97 - $11.81 $ 1.09-90%2013000
George Soros 2011-06-30 Sold Out $9.97 - $11.81 $ 1.09-90%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Enzon Pharmaceuticals Inc

GuruFocus Real Time Picks of the Week
The following information is a highlight of the real-time guru activity we saw this week. To view more information on these gurus, check out their guru portfolios. The “Real Time Picks” reports the stock purchases and sells that Gurus have made within the prior two weeks. If a Guru makes a purchase or sell of a company in which they own a greater-than 5% stake, SEC regulations require them to report their transaction within two days. This week we saw notable increases in Real Time activity from Seth Klarman (Trades, Portfolio), Jean-Marie Eveillard (Trades, Portfolio) and Chris Davis (Trades, Read more...
Seth Klarman Buys New Stock Kindred Biosciences, Cuts Stake in Enzon
Seth Klarman (Trades, Portfolio) of the Boston-based Baupost Group, which trades sparingly, has purchased a new stock: Kindred Biosciences (KIN), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 1.80
ENZN's P/E(ttm) is ranked higher than
100% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZN: 1.80 )
ENZN' s 10-Year P/E(ttm) Range
Min: 1.48   Max: 1354.17
Current: 1.8

1.48
1354.17
P/B 2.28
ENZN's P/B is ranked higher than
87% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. ENZN: 2.28 )
ENZN' s 10-Year P/B Range
Min: 0.95   Max: 13.17
Current: 2.28

0.95
13.17
P/S 1.43
ENZN's P/S is ranked higher than
96% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 20.06 vs. ENZN: 1.43 )
ENZN' s 10-Year P/S Range
Min: 0.96   Max: 11.93
Current: 1.43

0.96
11.93
PFCF 1.81
ENZN's PFCF is ranked higher than
100% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZN: 1.81 )
ENZN' s 10-Year PFCF Range
Min: 1.52   Max: 428
Current: 1.81

1.52
428
EV-to-EBIT 0.99
ENZN's EV-to-EBIT is ranked higher than
99% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZN: 0.99 )
ENZN' s 10-Year EV-to-EBIT Range
Min: 0.7   Max: 976.9
Current: 0.99

0.7
976.9
Shiller P/E 2.25
ENZN's Shiller P/E is ranked higher than
100% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZN: 2.25 )
ENZN' s 10-Year Shiller P/E Range
Min: 1.87   Max: 50.15
Current: 2.25

1.87
50.15
Current Ratio 27.51
ENZN's Current Ratio is ranked higher than
98% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ENZN: 27.51 )
ENZN' s 10-Year Current Ratio Range
Min: 0.97   Max: 48.41
Current: 27.51

0.97
48.41
Quick Ratio 27.51
ENZN's Quick Ratio is ranked higher than
98% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. ENZN: 27.51 )
ENZN' s 10-Year Quick Ratio Range
Min: 0.82   Max: 48.21
Current: 27.51

0.82
48.21

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.33
ENZN's Price/Net Cash is ranked higher than
96% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 80.40 vs. ENZN: 2.33 )
ENZN' s 10-Year Price/Net Cash Range
Min: 1.91   Max: 343.75
Current: 2.33

1.91
343.75
Price/Net Current Asset Value 2.33
ENZN's Price/Net Current Asset Value is ranked higher than
96% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 41.80 vs. ENZN: 2.33 )
ENZN' s 10-Year Price/Net Current Asset Value Range
Min: 1.91   Max: 127.5
Current: 2.33

1.91
127.5
Price/Tangible Book 2.28
ENZN's Price/Tangible Book is ranked higher than
91% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 8.73 vs. ENZN: 2.28 )
ENZN' s 10-Year Price/Tangible Book Range
Min: 1.64   Max: 412.5
Current: 2.28

1.64
412.5
Price/DCF (Projected) 0.35
ENZN's Price/DCF (Projected) is ranked higher than
100% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZN: 0.35 )
ENZN' s 10-Year Price/DCF (Projected) Range
Min: 0.33   Max: 65.35
Current: 0.35

0.33
65.35
Price/Median PS Value 0.51
ENZN's Price/Median PS Value is ranked higher than
94% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. ENZN: 0.51 )
ENZN' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 53.23
Current: 0.51

0.48
53.23
Price/Graham Number 0.43
ENZN's Price/Graham Number is ranked higher than
99% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ENZN: 0.43 )
ENZN' s 10-Year Price/Graham Number Range
Min: 0.41   Max: 91.67
Current: 0.43

0.41
91.67
Earnings Yield (Greenblatt) 101.00
ENZN's Earnings Yield (Greenblatt) is ranked higher than
92% of the 475 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ENZN: 101.00 )
ENZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 140
Current: 101

0.1
140
Forward Rate of Return (Yacktman) 15.89
ENZN's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -10.16 vs. ENZN: 15.89 )
ENZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.1   Max: 30.5
Current: 15.89

-0.1
30.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EZ1.Germany
Enzon Pharmaceuticals, Inc., a biotechnology company, was founded on 1981. The Company is engaged in the research and development of therapeutics for cancer patients primarily in the United States. Its drug development programs utilize two platforms - Customized PEGylation Linker Technology and third-generation messenger ribonucleic acid antagonists utilizing the Locked Nucleic Acid technology. Its development pipeline comprises various novel compounds, including PEG-SN38, which is in Phase II clinical trials for the treatment of metastatic colorectal and breast cancer; and Phase I trial for pediatric patients with cancer. Its development pipeline also includes mRNA antagonists, such as hypoxia-inducible factor-1 alpha that is in Phase I study in patients with solid tumors and lymphoma to evaluate various dosing schedules; Survivin, which is in Phase I study in patients with solid tumors and lymphoma; and androgen receptor, a novel antagonist that is in Phase I study in patients with castration-resistant prostate cancer. In addition, the company has LNA targets in various stages of preclinical research. It has collaboration agreement with National Cancer Institute for conducting a pilot study in patients with tumors in the liver; and has a license and collaboration agreement with Santaris Pharma A/S for mRNA antagonists. The Company has a strategic alliance with Zhejiang Hisun Pharmaceuticals Co. Ltd for the research and development of therapeutics using the company's customized PEGylation linker technology.
» More Articles for ENZN

Headlines

Articles On GuruFocus.com
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
GuruFocus Real Time Picks of the Week Jan 10 2014 
Seth Klarman Buys New Stock Kindred Biosciences, Cut Stake in Enzon Jan 10 2014 
Billionaires Hold Bargains, 40% Off or More Sep 11 2013 
Charles Brandes Top Second Quarter Portfolio Changes Aug 09 2013 
First Pacific Advisors’ Top New Buys Aug 08 2012 
Enzon Inc. Reports Operating Results (10-K) Mar 16 2011 
Carl Icahn Buys NAV, CHK, ENZN, AMLN, CMC, Feb 15 2011 
Despite Bearish View, Seth Klarman Holds These Stocks: VSAT, THRX, NWSA, BBEP, ENZN, CSE Nov 25 2010 
Enzon Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Bankruptcy Filing Fallout Continues For NII Holdings Sep 19 2014
ENZON PHARMACEUTICALS INC Financials Aug 19 2014
ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
Enzon regains compliance with Nasdaq Jul 16 2014
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 16 2014
Enzon Pharmaceuticals Inc Stock Upgraded (ENZN) Jul 08 2014
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Jun 12 2014
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... May 30 2014
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 19 2014
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... May 09 2014
ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 09 2014
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... May 01 2014
Enzon Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards May 01 2014
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Mar 25 2014
ENZON PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 14 2014
Warning! Enzon Pharmaceuticals Is Definitely Going To $0 Jan 14 2014
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other... Dec 16 2013
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events Dec 05 2013
ENZON PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Nov 21 2013
ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 12 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK